상세정보
Export to Refworks부가기능
Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop/ Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. |
| 개인저자 | Balogh, Erin,rapporteur. Maxfield, Kimberly,rapporteur, Patlak, Margie,rapporteur, Nass, Sharyl J.,rapporteur, |
| 단체저자명 | National Cancer Policy Forum (U.S.),sponsoring body. |
| 발행사항 | Washington, DC: The National Academies Press, [2016]. |
| 형태사항 | 1 online resource (xxii, 112 pages): color illustrations. |
| 기타형태 저록 | Print version: Policy issues in the clinical development and use of immunotherapy for cancer treatment. Washington : National Academies Press, 2016 030944232X |
| ISBN | 9780309442336 0309442338 |
| 서지주기 | Includes bibliographical references (pages 94-102). |
| 요약 | "Immunotherapy is a form of cancer therapy that harnesses the body immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop"--Publisher's description. |
| 회의명 | Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment (Workshop) (2016 : Washington, D.C.), |
| 일반주제명 | Cancer --Immunotherapy --Congresses. Neoplasms --immunology. Neoplasms --therapy. Immunotherapy. Immunotherapy --adverse effects. Cancer --Immunotherapy. MEDICAL / Oncology |
| 언어 | 영어 |
| 바로가기 |  |
